Showing results (91-100 of 436) with videos related to
Sort By:
Pageof 44
Zeitschrift Fur Gastroenterologie|January 12, 2026
Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's diseaseJagoda Pokryszka, Christian Primas, Michael Stadlmann, et al.Pharmaceutics|September 28, 2021
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel DiseaseChristina Schräpel, Lukas Kovar, Dominik Selzer, et al.Journal of Crohn'S & Colitis|August 12, 2025
Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical TrialsHasan Hamam, Parambir S Dulai, John K Marshall, et al.Journal of Crohn'S & Colitis|February 23, 2023
Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY studyEmily C L Wong, Parambir S Dulai, Badar Hasan, et al.Journal of Crohn'S & Colitis|January 13, 2025
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Inflammatory Bowel Diseases|June 28, 2022
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.The American Journal of Gastroenterology|January 18, 2024
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.The American Journal of Gastroenterology|April 18, 2022
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2015
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trialsAnthony Lopez, Alexander C Ford, Jean-Frédéric Colombel, et al.Inflammatory Bowel Diseases|November 24, 2025
Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Pageof 44